

EXHIBIT H



LATEST NEWS

23/08/2006

ABLYNX COMPLETES €40 MILLION (~US\$50 MILLION) SERIES C FINANCING - ONE OF THE LARGEST PRIVATE PLACEMENTS IN EUROPEAN BIOTECH THIS YEAR

01/06/2006

ABLYNX STRENGTHENS MANAGEMENT TEAM - EVA-LOTTA ALLAN JOINS AS CHIEF BUSINESS OFFICER

18/05/2006

ABLYNX APPOINTS WIM OTTEVAERE AS CFO

10/04/2006

ABLYNX AND PROCTER & GAMBLE EXTEND NANOBODY™ DRUG DISCOVERY AND DEVELOPMENT AGREEMENT TO METABOLIC TARGETS

27/03/2006

ABLYNX APPOINTS EDWIN MOSES AS CEO

14/03/2006

ABLYNX REVEALS POWER OF NANOCLOONE™ - A HIGH THROUGHPUT METHOD FOR ISOLATING HIGH POTENT ANTIBODY-DERIVED THERAPEUTIC PROTEINS (NANOBODIES™)

more news > >

WELCOME TO ABLYNX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies™ to treat a range of serious human diseases. Nanobodies™ are a novel class of antibody-derived therapeutic proteins. Because of their small size, unique structure and unparalleled stability, Nanobodies™ combine the advantages of conventional antibody therapeutics with key features of small-molecule drugs.

Ablynx is the only company in the World with granted US and European composition of matter patents describing Nanobodies™.


The power of Ablynx's discovery platform has resulted in a number of Nanobody™ drug candidates in pre-clinical development at the company's headquarters in Ghent, Belgium. Ablynx is a spin-off of the Flanders Interuniversity Institute for Biotechnology (VIB).

read more > >



UNDERSTANDING NANOBODIES™

Nanobodies™ are antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies. The Nanobody™ technology was originally developed following the discovery that camelidae (camels and llamas) possess fully functional antibodies that lack light chains. These heavy-chain antibodies contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Importantly, the cloned and isolated VHH domain is a perfectly stable polypeptide harboring the full antigen-binding capacity of the original heavy-chain antibody. The unique structural and functional properties of this newly discovered VHH domain are the basis of Ablynx's Nanobodies™.



Ablynx's Nanobodies™ combine the advantages of conventional antibodies with important features of small molecule drugs. Like conventional antibodies, Nanobodies™ show high target specificity and low inherent toxicity; however, like small molecule drugs they can inhibit enzymes and can access receptor clefts. Furthermore, Nanobodies™ are extremely stable, can be administered by means other than injection, and are easy to manufacture.

Ablynx's Nanobodies™ have a high homology with the VH domains of human antibodies and can be further humanized without any loss of activity. Importantly, Nanobodies™ have an extremely low immunogenic potential. In initial primate studies with Nanobody™ lead compounds, repeated administration did not yield a detectable immune response.

[back to top](#)



PUBLICATIONS

Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Bajyana Songa E, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. **Nature** 1993 June 3; 363 (6428): 446-8.

Davies J, Riechmann L. 'Camelising' human antibody fragments: NMR studies on VH domains. **FEBS Lett.** 1994 Feb 21; 339(3): 285-90.

Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA and Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. **Protein Eng.** 1994 Sep; 7(9): 1129-3.

Davies J, Riechmann L. Antibody VH domains as small recognition units. **Biotechnology (NY)** 1995 May; 13(5): 475-9.

Gharoudi MA, Desmyter A, Muyldermans S, Hamers R. Identification of soluble, stable camel VH antibody fragments expressed in *E.coli*, with specificity and neutralizing activity for tetanus toxoid. **9th Forum of Applied Biotechnology, Med. Fac. Landbouw Univ. Gent.** 1995; 60/4a part I: 2097-2100.

Davies J, Riechmann L. Single antibody domains as small recognition units: design and in vitro antigen selection of camelised, human VH domains with improved protein stability. **Protein Eng.** 1996 Jun; 9(6): 531-7.

Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, Hamers R, Muyldermans S, Wyns L. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. **Nat Struct Biol.** 1996 Sep; 3(9): 803-11.

Sheriff S, Constantine KL. Redefining the minimal antigen-binding fragment. **Nat Struct Biol.** 1996 Sep; 3(9): 733-6.

Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrrips T, Anguille C, Cambillau C, Tegoni M. The crystal structure of a llama heavy chain variable domain. **Nat Struct Biol.** 1996 Sep; 3(9): 752-7.

Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. **FEBS Lett.** 1997 Sep 15; 414(3): 521-6.

Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Comparison of llama VH sequences from conventional and heavy chain antibodies. **Mol Immunol.** 1997 Nov-Dec; 34(16-17): 1121-31.

Atarhouch T, Bendahman N, Hamers-Casterman C, Hamers R, Muyldermans S. cDNA sequence coding for the constant region of the dromedary g3 heavy-chain antibody. **Journal of Camel Practice and Research** 1997; 4: 177-182.

Nguyen VK, Muyldermans S, Hamers R. The specific variable domain of camel heavy-chain antibodies is encoded in the germline. **J Mol Biol.** 1998 Jan 23; 275(3): 413-8

Lauwereys M, Ghahroudi MA, Desmyter A, Kinne J, Hölder W, De Genst E, Wyns L, Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. **EMBO J.** 1998 Jul 1; 17(13): 3512-20.

Frenken LG, Hessing JG, Van den Hondel CA, Verrrips CT. Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. **Res Immunol.** 1998 Jul-Aug;149(6):589-99.

Transue TR, De Genst E, Ghahroudi MA, Wyns L, Muyldermans S. Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. **Proteins** 1998 Sep 1; 32(4): 515-22.

Muyldermans S, Lauwereys M. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. **J Mol Recognit.** 1999 Mar-Apr; 12 (2): 131-40.

van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P, Verrrips CT. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. **Biochim Biophys Acta** 1999 Apr 12; 1431(1): 37-46.

Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, Wyns L. A single-domain antibody fragment in complex with Rnase A: non canonical loop structures and nanomolar affinity using two CDR loops. **Structure Fold Des.** 1999 Apr 15; 7(4): 361-70.

Ngyuen VK, Hamers R, Wyns L, Muyldermans S. Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of functional camel IgG2a heavy-chain antibodies. **Mol Immunol.** 1999 Jun; 36(8): 515-24.

Woolven BP, Frenken LG, van der Logt P, Nicholls PJ. The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. **Immunogenetics** 1999 Oct; 50 (1-2): 98-101.

Riechmann L, Muyldermans S. Single domain antibodies: Comparison of camel VH and camelised-human VH domains. **J Immunol Methods** 1999 Dec 10; 231 (1-2): 25-38.

Spinelli S, Frenken LG, Hermans P, Verrrips T, Brown K, Tegoni M, Cambillau C. Camelid heavy-chain variable domains provide efficient combining sites to haptens. **Biochemistry** 2000 Feb 15; 39(6): 1217-22.

Frenken LG, van der Linden RH, Hermans PW, Bos JW, Ruuls RC, de Geus B, Verrrips CT. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by *Saccharomyces cerevisiae*. **J Biotechnol.** 2000 Feb 28; 78(1): 11-21.

Nguyen VK, Hamers R, Wyns L, Muyldermans S. Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. **EMBO J.** 2000 Mar 1; 19(5): 921-30.

van der Linden R, de Geus B, Stok W, Bos W, van Wassenaar D, Verrrips T, Frenken L. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of *Lama glama*. **J Immunol Methods** 2000 Jun 23; 240 (1-2): 185-95.

Decanniere K, Muyldermans S, Wyns L. Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes?. **J Mol Biol.** 2000 Jun 30; 300 (1): 83-91.

van der Linden RH, de Geus B, Frenken GJ, Peters H, Verrrips CT. Improved production and function of llama heavy chain antibody fragments by molecular evolution. **J Biotechnol.** 2000 Jul 14; 80(3): 261-70.

Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, De Geus B. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. **Mol Immunol.** 2000 Aug; 37(10): 579-90.

Perez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, Darbon H, Frenken LG. Thermal unfolding of a llama antibody fragment: a two-state reversible process. **Biochemistry** 2001 Jan 9; 40(1): 74-83.

Conrath KE, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. **J Biol Chem.** 2001 Mar 9; 276 (10): 7346-50.

Muyldermans S, Cambillau C, Wyns L. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. **Trends Biochem Sci.** 2001 Apr;26(4):230-5.

Muyldermans S. Single domain camel antibodies: current status. **J Biotechnol.** 2001 Jun; 74 (4): 277-302.

Desmyter A, Decanniere K, Muyldermans S, Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. **J Biol Chem.** 2001 Jul 13; 276 (28): 26285-90.

Spinelli S, Tegoni M, Frenken L, van Vliet C, Cambillau C. Lateral recognition of a dye hapten by a llama VHH domain. **J Mol Biol.** 2001 Aug 3; 311 (1): 123-9.

Conrath KE, Lauwereys M, Galleni M, Matagne A, Frère JM, Kinne J, Wyns L, Muyldermans S. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in Camelidae. **Antimicrob Agents Chemother.** 2001 Oct; 45 (10): 2807-12.

Decanniere K, Transue TR, Desmyter A, Maes D, Muyldermans S, Wyns L. Degenerate interfaces in antigen-antibody complexes. **J Mol Biol.** 2001 Oct 26; 313(3): 473-8.

Nguyen VK, Desmyter A, Muyldermans S. Functional heavy-chain antibodies in Camelidae. **Adv Immunol.** 2001; 79: 261-96.

Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. **FASEB J.** 2002 Feb; 16 (2): 240-2.

Ewert S, Cambillau C, Conrath K and Plückthun A. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. **Biochemistry** 2002 Mar 19; 41 (11): 3628-36.

Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A. Single-domain antibody fragments with high conformational stability. **Protein Sci.** 2002 Mar; 11 (3): 500-15.

Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh-G, Gobert M, Muyldermans S, De Baetselier P, Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. **Int J Cancer.** 2002 Mar 20; 98 (3): 456-62.

Su C, Nguyen VK, Nei M. Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids. **Mol Biol Evol.** 2002 Mar; 19 (3): 205-15.

van der Vaart JM. Expression of VHH antibody fragments in *Saccharomyces cerevisiae*. **Methods Mol Biol.** 2002; 178: 359-66.

Vranken W, Tolkatchev D, Xu P, Tanha J, Chen Z, Narang S, Ni F. Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface. **Biochemistry** 2002 Jul 9; 41 (27): 8570-9.

Nguyen VK, Su C, Muyldermans S, Van der Loo W. Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. **Immunogenetics** 2002 Apr; 54 (1): 39-47.

Renisio JG, Perez J, Czisch M, Guenneugues M, Bornet O, Frenken L, Cambillau C, Darbon H. Solution structure and backbone dynamics of an antigen-free heavy chain variable domain (VHH) from llama. **Proteins** 2002 Jun 1; 47 (4): 546-55.

Desmyter A, Spinelli S, Payan F, Lauwereys M, Wyns L, Muyldermans S, Cambillau C. Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. **J Biol Chem.** 2002 Jun 28; 277 (26): 23645-50.

Leedeboer AM, Bezemer S, de Haard JJ, Schaffers IM, Verrrips CT, van Vliet C, Dusterhoff EM, Zoon P, Moineau S, Frenken LG. Preventing phage lysis of *Lactococcus lactis* in cheese production using a neutralizing heavy-chain antibody fragment from llama. **J Dairy Sci.** 2002 Jun; 85 (6): 1376-82.

De Genst E, Areskoug D, Decanniere K, Muyldermans S, Andersson K. Kinetic and affinity predictions of a

protein-protein interaction using multivariate experimental design. **J Biol Chem.** 2002 Aug 16; 277 (33): 29897-907.

Ferrat G, Renisio JG, Morelli X, Slootstra J, Meloen R, Cambillau C, Darbon H. A peptide mimic of an antigen loop of alfa-human chorionic gonadotropin hormone: solution structure and interaction with a llama VHH domain. **Biochem J.** 2002 Sep 1; 366 (Pt 2): 415-22.

Thomassen YE, Meijer W, Sierkstra L, Verrips CT. Large-scale production of VHH antibody fragments by *Saccharomyces cerevisiae*. **Enzyme and Microbial Technol.** 2002; 30: 273-8.

Harmsen MM, Smits CB, De Geus B. Stimulation of chymosin secretion by simultaneous expression with chymosin-binding llama single-domain antibody fragments in yeast. **Appl Microbiol Biotechnol.** 2002 Dec; 60 (4): 449-54.

Jobling SA, Jarman C, Teh MM, Holmberg N, Blake C, Verhoeven ME. Immunomodulation of enzyme function in plants by single-domain antibody fragments. **Nat Biotechnol.** 2003 Jan; 21 (1): 77-80.

Conrath KE, Wernery U, Muyldermans S, Nguyen VK. Emergence and evolution of functional heavy-chain antibodies in Camelidae. **Dev Comp Immunol.** 2003 Feb; 27 (2): 87-103.

Pleschberger M, Neubauer A, Egelseer EM, Weigert S, Lindner B, Sleytr UB, Muyldermans S, Sara M. Generation of a functional monomolecular protein lattice consisting of an S-layer fusion protein comprising the variable domain of a camel heavy chain antibody. **Bioconjug Chem.** 2003 Mar-Apr; 14 (2): 440-8.

Lah J, Marianovsky I, Glaser G, Engelberg-Kulka H, Kinne J, Wyns L, Loris R. Recognition of the intrinsically flexible addiction antidote *MazE* by a dromedary single domain antibody fragment. **J Biol Chem.** 2003 Apr 18; 278 (16): 14101-11.

Nguyen VK, Zou X, Lauwereys M, Brys L, Bruggemann M, Muyldermans S. Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells. **Immunology.** 2003 May; 109 (1): 93-101.

Joosten V, Lokman C, Van Den Hondel CA, Punt PJ. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. **Microb Cell Fact.** 2003 Jan 30; 2 (1): 1.

Li CH, Ma XH, Chen WZ, Wang CX. A soft docking algorithm for predicting the structure of antibody-antigen complexes. **Proteins** 2003 Jul 1; 52 (1): 47-50.

Loris R, Marianovsky I, Lah J, Laeremans T, Engelberg-Kulka H, Glaser G, Muyldermans S, Wyns L. Crystal structure of the intrinsically flexible addiction antidote *MazE*. **J Biol Chem.** 2003 Jul 25; 278 (30): 28252-7.

van Koningsbruggen S, de Haard H, de Kievit P, Dirks RW, van Remoortere A, Groot AJ, van Engelen BG, den Dunnen JT, Verrips CT, Frants RR, van der Maarel SM. Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy. **J Immunol Methods.** 2003 Aug; 279 (1-2): 149-61.

Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, Larsson G, Spencer A, Archer DB, Sasse J, Muyldermans S, Wyns L, Redfield C, Matagne A, Robinson CV, Dobson CM. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. **Nature.** 2003 Aug 14; 424 (6950): 783-8.

Bond CJ, Marsters JC, Sidhu SS. Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naïve antibody libraries. **J Mol Biol.** 2003 Sep 19; 332 (3): 643-55.

Yau KY, Groves MA, Li S, Sheedy C, Lee H, Tanha J, MacKenzie CR, Jermutus L, Hall JC. Selection of haptenspecific single-domain antibodies from a non-immunized llama ribosome display library. **J Immunol Methods.** 2003 Oct 1; 281 (1-2): 161-75.

Dekker S, Toussaint W, Panayotou G, de Wit T, Visser P, Grosveld F, Drabek D. Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses. **J Virol.** 2003 Nov; 77 (22): 12132-9.

Verheesen P, Ten Haaf MR, Lindner N, Verrips CT, de Haard JJ. Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. **Biochim Biophys Acta** 2003 Dec 5; 1624 (1-3): 21-8.

Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, Stone E, Brisson JR, MacKenzie CR. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. **J Mol Biol.** 2004 Jan 2; 335 (1): 49-56.

Stijlemans B, Conrath K, Cortez-Retamozo V, Xong HV, Wyns L, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S. Efficient targeting of conserved cryptic epitopes of infectious agents by single-domain antibodies. African trypanosomes as paradigm. **J Biol Chem.** 2004 Jan 9; 279 (2): 1256-61.

Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. Efficient cancer therapy with a nanobody-based conjugate. **Cancer Res.** 2004 Apr 15; 64 (8): 2853-7.

Spinelli S, Desmyter A, Frenken L, Verrips T, Tegoni M, Cambillau C. Domain swapping of a llama VHH domain builds a crystal-wide beta-sheet structure. **FEBS Lett.** 2004 Apr 23; 564 (1-2): 35-40.

Pleschberger M, Saerens D, Weigert S, Sleytr UB, Muyldermans S, Sara M, Egelseer EM. An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. **Biocjug Chem.** 2004 May-Jun; 15 (3): 664-71.

Nicaise M, Valerio-Lepiniec M, Minard P, Desmadril M. Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold. **Protein Sci.** 2004 Jul; 13 (7): 1882-91.

Zhang J, Li Q, Nguyen TD, Tremblay TL, Stone E, To R, Kelly J, Roger MacKenzie C. A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. **J Mol Biol.** 2004 Jul 30; 341 (1): 161-9.

Omida K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Bakhtiari A, Paknejad M, Kashanian S. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in *Camelus bactrianus*. **Tumour Biol.** 2004 Jul-Aug; 25 (4): 179-87.

Omida K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Golmakani N. Production of a novel camel single-domain antibody specific for the type III mutant EGFR. **Tumour Biol.** 2004 Sep-Dec; 25 (5-6): 296-305.

Szynol A, de Soet JJ, Sieben-van Tuyl E, Bos JW, Frenken LG. Bactericidal effects of a fusion protein of llama heavy-chain antibodies coupled to glucose oxidase on oral bacteria. **Antimicrob Agents Chemother.** 2004 Sep; 48 (9): 3390-5.

Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, Conrath K. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. **J Biol Chem.** 2004 Dec 10; 279 (50): 51965-72.

De Genst E, Handelberg F, Van Meirhaeghe A, Vynck S, Loris R, Wyns L, Muyldermans S. Chemical basis for the affinity maturation of a camel single domain antibody. **J Biol Chem.** 2004 Dec 17; 279 (51): 53593-601.

Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. **Expert Opin Biol Ther.** 2005 Jan; 5 (1): 111-24.

Dolk E, van der Vaart M, Lutje Hulst D, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L, Verrips T. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. **Appl Environ Microbiol.** 2005 Jan; 71(1): 442-50.

Joosten V, Gouka RJ, van den Hondel CA, Verrips CT, Lokman BC. Expression and production of llama variable heavy-chain antibody fragments (V(HH)s) by *Aspergillus awamori*. **Appl Microbiol Biotechnol.** 2005 Jan; 66 (4): 384-92.

Dumoulin M, Canet D, Last AM, Pardon E, Archer DB, Muyldermans S, Wyns L, Matagne A, Robinson CV, Redfield C, Dobson CM. Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations. **J Mol Biol.** 2005 Feb 25; 346 (3): 773-88.

Yau KY, Dubuc G, Li S, Hirama T, Mackenzie CR, Jermytus L, Hall JC, Tanha J. Affinity maturation of a V (H)H by mutational hotspot randomization. **J Immunol Methods.** 2005 Feb; 297 (1-2): 213-24.

De Genst E, Silence K, Ghahroudi MA, Decanniere K, Loris R, Kinne J, Wyns L, Muyldermans S. Strong in vivo maturation compensates for structurally restricted H3 loops in antibody repertoires. **J Biol Chem.** 2005 Apr 8; 280 (14): 14114-21.

Huang Y, Verheesen P, Roussis A, Frankhuizen W, Ginjaar I, Haldane F, Laval S, Anderson LV, Verrrips T, Frants RR, de Haard H, Bushby K, den Dunnen J, van der Maarel SM. Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. **Eur J Hum Genet.** 2005 Apr 13.

Dolk E, van Vliet C, Perez JM, Vriend G, Darbon H, Ferrat G, Cambillau C, Frenken LG, Verrrips T. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. **Proteins.** 2005 May 15; 59 (3): 555-64.

Bond CJ, Wiesmann C, Marsters JC Jr, Sidhu SS. A structure-based database of antibody variable domain diversity. **J Mol Biol.** 2005 May 6; 348 (3): 699-709.

Zarebski LM, Urrutia M, Goldbaum FA. Llama single domain antibodies as a tool for molecular mimicry. **J Mol Biol.** 2005 Jun 17; 349 (4): 814-24.

Conrath K, Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, Wyns L, Muyldermans S, Loris R. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. **J Mol Biol.** 2005 Jul 1; 350 (1): 112-25.

De Haard HJ, Bezemer S, Ledeboer AM, Muller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrrips CT. Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. **J Bacteriol.** 2005 Jul; 187(13): 4531-41.

Gibbs WW. Nanobodies. **Sci Am.** 2005 Aug; 293 (2): 78-83.

Thomassen YE, Verkleij AJ, Boonstra J, Verrrips CT. Specific production rate of VHH antibody fragments by *Saccharomyces cerevisiae* is correlated with growth rate, independent of nutrient limitation. **J Biotechnol.** 2005 Aug 22; 118 (3): 270-7.

Hoogenboom HR. Selecting and screening recombinant antibody libraries. **Nat Biotechnol.** 2005 Sep; 23 (9): 1105-16.

Zou X, Smith JA, Nguyen VK, Ren L, Luyten K, Muyldermans S, Bruggemann M. Expression of a dromedary heavy chain-only antibody and B cell development in the mouse. **J Immunol.** 2005 Sep 15; 175 (6): 3769-79.

Huang L, Reekmans G, Saerens D, Friedt JM, Frederix F, Francis L, Muyldermans S, Campitelli A, Van Hoof C. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. **Biosens Bioelectron.** 2005 Sep 15; 21(3):483-90.

Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, Matagne A, Wyns L, Muyldermans S, Conrath K. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. **J Mol Biol.** 2005 Sep 23; 352 (3): 597-607.

Harmsen MM, Van Solt CB, Fijten HP, Van Setten MC. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. **Vaccine.** 2005 Sep 30; 23 (41): 4926-34.

Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the

gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. **Blood**. 2005 Nov 1; 106 (9): 3035-42.

Dejaegere A, Choulier L, Lafont V, De Genst E, Altschuh D. Variations in antigen-antibody association kinetics as a function of pH and salt concentration: a QSAR and molecular modeling study. **Biochemistry**. 2005 Nov 8; 44 (44): 14409-18.

Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. **J Neurochem**. 2005 Nov; 95 (4): 1201-14.

Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam M, Allameh AA. High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in *Escherichia coli*. **Protein Expr Purif**. 2005 Nov; 44(1): 32-8.

Harmsen MM, van Solt CB, Hoogendoorn A, van Zijderveld FG, Niewold TA, van der Meulen J. *Escherichia coli* F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. **Vet Microbiol**. 2005 Nov 30; 111 (1-2): 89-98.

Saerens D, Frederix F, Reekmans G, Conrath K, Jans K, Brys L, Huang L, Bosmans E, Maes G, Borghs G, Muyldermans S. Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. **Anal Chem**. 2005 Dec 1; 77 (23): 7547-55.

Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. **Cancer Metastasis Rev**. 2005 Dec; 24 (4): 501-19.

Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh A, Sarrami R, Nasiry H, Sadeghizadeh M. The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin. **Immunol Invest**. 2005; 34 (4): 431-52.

Verheesen P, de Kluijver A, van Koningsbruggen S, de Brij M, de Haard HJ, van Ommen GJ, van der Maarel SM, Verrips CT. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. **Hum Mol Genet**. 2006 Jan 1; 15 (1): 105-11.

Spinelli S, Desmyter A, Verrips CT, de Haard HJ, Moineau S, Cambillau C. Lactococcal bacteriophage p2 receptor-binding protein structure suggests a common ancestor gene with bacterial and mammalian viruses. **Nat Struct Mol Biol**. 2006 Jan; 13 (1): 85-9.

Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, Niewold TA, van Zijderveld FG. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. **Appl Microbiol Biotechnol**. 2006 Feb 1; 1-8

Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh AA. Over expression of anti-MUC1 single-domain antibody fragments in the yeast *Pichia pastoris*. **Mol Immunol**. 2006 Feb; 43 (5): 426-35.

Marquardt A, Muyldermans S, Przybylski M. A synthetic camel anti-lysozyme peptide antibody (peptibody) with flexible loop structure identified by high-resolution affinity mass spectrometry. **Chemistry**. 2006 Feb 20; 12 (7): 1915-23.

Harrison RA, Hasson SS, Harmsen M, Laing GD, Conrath K, Theakston RD. Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. **Toxicon**. 2006 Mar; 47 (3): 364-8.

De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S, Wyns M. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. **Proc Natl Acad Sci U S A**. 2006 Mar 21; 103 (12): 4586-91.

Groot AJ, Verheesen P, Westerlaken EJ, Gort EH, van der Groep P, Bovenschen N, van der Wall E, van Diest PJ, Shvarts A. Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha. **Lab Invest**. 2006 Apr; 86 (4): 345-56.

Kruger C, Hultberg A, Marcotte H, Hermans P, Bezemer S, Frenken LG, Hammarstrom L. Therapeutic effect of llama derived VH fragments against *Streptococcus mutans* on the development of dental caries. **Appl Microbiol Biotechnol.** 2006 Apr 25.

Tremblay DM, Tegoni M, Spinelli S, Campanacci V, Blangy S, Huyghe C, Desmyter A, Labrie S, Moineau S, Cambillau C. Receptor-binding protein of *Lactococcus lactis* phages: identification and characterization of the saccharide receptor-binding site. **J Bacteriol.** 2006 Apr; 188 (7): 2400-10.

van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, Sarker SA, van der Logt CP, Svensson L, Verrrips CT, Hammarstrom L, van Klinken BJ. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. **Vaccine.** 2006 May 8; 24 (19): 4130-7.

Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen En Henegouwen PM. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies. **Cancer Immunol Immunother.** 2006 May 30

Davis FP, Braberg H, Shen MY, Pieper U, Sali A, Madhusudhan MS. Protein complex compositions predicted by structural similarity. **Nucleic Acids Res.** 2006 May 31; 34 (10): 2943-52.

Coppiepers K, Dreier T, Silence K, Haard HD, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Wiele CV, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P. Formatted anti-tumor necrosis factor alpha VH fragments derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. **Arthritis Rheum.** 2006 Jun; 54 (6): 1856-66.

De Genst E, Saerens D, Muyldermans S, Conrath K. Antibody repertoire development in camelids. **Dev Comp Immunol.** 2006; 30 (1-2): 187-98.

Ladenson RC, Crimmins DL, Landt Y, Ladenson JH. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. **Anal Chem.** 2006 Jul 1; 78 (13): 4501-8.

Lewis W, Keshavarz-Moore E, Windust J, Bushell D, Parry N. Construction and evaluation of novel fusion proteins for targeted delivery of micro particles to cellulose surfaces. **Biotechnol Bioeng.** 2006 Jul 5; 94 (4): 625-32.

[^](#) back to top